Showing 2851-2860 of 7016 results for "".
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
https://reachmd.com/programs/neurofrontiers/raise-subgroup-analysis-zilucoplan/51013/New Contact Lens Technology for Patients With Presbyopia, Dry Eye Disease, and Ocular Surface Disease
https://reachmd.com/programs/empower/new-contact-lens-technology-for-patients-with-presbyopia-dry-eye-disease-and-ocular-surface-disease/56897/A practical guide for new contact lens patients.FA hiPSCs in Translational Drug Development
https://reachmd.com/programs/neurofrontiers/fa-hipscs-translational-drug-development/54667/Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
https://reachmd.com/programs/neurofrontiers/omaveloxolone-in-friedreichs-ataxia-early-real-world-signals/54666/Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
https://reachmd.com/programs/cme/evaluating-use-in-pancreatic-cancer-efficacy-and-safety-data-for-on-state-ras-inhibitors/54122/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Rethinking the Routine: Moving from Topicals to Systemics in Psoriasis
https://reachmd.com/programs/dermconsult/topicals-systemics-psoriasis/39680/Psoriasis management isn’t one-size-fits-all—especially when it comes to sequencing therapies. Hear Dr. Christopher Bunick outline his evidence-based approach to transitioning patients from topical to systemic treatments, including key criteria for defining topical failure, the systemic nature of psHow Generation X Is Shaping Aesthetic Practice Strategies of the Future
https://reachmd.com/programs/modern-aesthetics/how-generation-x-is-shaping-aesthetic-practice-strategies-of-the-future/49008/The Future of Oral SERDs: Combination Strategies
https://reachmd.com/programs/cme/the-future-of-oral-serds-combination-strategies/39801/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Europe: Adapting the Evidence
https://reachmd.com/programs/cme/spotlight-on-europe-adapting-the-evidence/39808/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.New Insights in the Management of HCM: Exploring the Clinical Spectrum
https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/Explore personalized strategies in obstructive HCM, from diagnosis to treatment evolution, including real-world insights into cardiac myosin inhibitor use.